10 Best Mid Cap Pharma Stocks to Buy

7. Guardant Health Inc. (NASDAQ:GH)

Market Capitalization as of July 22: $5.67 billion

Number of Hedge Fund Holders: 43

Guardant Health Inc. (NASDAQ:GH) is one of the best mid cap pharma stocks to buy. On July 15, Guardant Health announced the enrollment of the first patient in the National Cancer Institute’s/NCI’s Vanguard Study. The 4-year study aims to enroll up to 24,000 participants to evaluate the feasibility of using multi-cancer detection/MCD tests in future randomized controlled trials.

Guardant’s Shield MCD test was selected for the study. The Shield MCD test was chosen for its overall performance in detecting 10 cancer types: lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver, and gastric. Data supporting its performance was presented at the 2025 American Society of Clinical Oncology/ASCO Annual Meeting in Chicago.

The Vanguard Study was initiated following review and approval by the US FDA as part of the NCI’s submission for an investigational device exemption/IDE. The Vanguard Study, conducted by the Cancer Screening Research, is enrolling individuals aged 45-75 who do not currently have cancer and have not received a cancer diagnosis in the past 5 years.

Guardant Health Inc. (NASDAQ:GH) is a precision oncology company that provides blood and tissue tests and data sets in the US and internationally.